Mode
Text Size
Log in / Sign up

albuterol

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of albuterol

44 trials tracked of albuterol: 25 in phase 3 or 4 and 7 with published results. The most-cited published study has 253 citations.

44Trials tracked
25Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 11 Phase 3 14 Phase 2 7 Phase 1 2 Other / NA 10
  1. Phase 3 Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial Completed · 253 cited
  2. Phase 3 Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2) Completed · 171 cited
  3. Phase 4 A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects Completed · 64 cited
  4. Phase 3 A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With Asthma Completed · 40 cited
  5. Phase 3 A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma Completed · 11 cited
  6. Phase 3 Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Completed · 5 cited
Show 38 more trials
  1. Phase 3 Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study) Completed · 1 cited
  2. Phase 4 A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD Completed
  3. Phase 4 A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma Completed
  4. Phase 4 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Completed
  5. Phase 4 A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma Completed
  6. Phase 4 Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma Completed
  7. Phase 4 Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB) Completed
  8. Phase 4 Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed
  9. Phase 4 Dose-response of Albuterol in Asthmatics Completed
  10. Phase 4 Effect of Nebulized Bronchodilators on Heart Rate Completed
  11. Phase 4 Dose-Response of Salmeterol in Children Completed
  12. Phase 3 Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma Completed
  13. Phase 3 A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Asthma Completed
  14. Phase 3 A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma Completed
  15. Phase 3 Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics Completed
  16. Phase 3 (CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA) Completed
  17. Phase 3 Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room. Completed
  18. Phase 3 A Chronic Obstructive Pulmonary Disease (COPD) Trial Investigating Roflumilast on Safety and Effectiveness in China, Hong Kong and Singapore: Completed
  19. Phase 3 Albuterol HFA MDI in Pediatric Participants With Asthma Completed
  20. Phase 2 Effect of Inhaled Albuterol in Pulmonary Hypertension Completed
  21. Phase 2 The Effect of Nebulized Albuterol on Donor Oxygenation Completed
  22. Phase 2 Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease Completed
  23. Phase 2 Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects Completed
  24. Phase 2 Efficacy, Safety, and Tolerability of Dupilumab in Patients With Persistent Moderate to Severe Eosinophilic Asthma Completed
  25. Phase 2 Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease Completed
  26. Phase 2 A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma Completed
  27. Phase 1 A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol Completed
  28. Phase 1 Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype Completed
  29. N/A Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma Completed
  30. N/A Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis Completed
  31. N/A Sensor and Electronic Health Records (EHR) Integration Pilot Study Completed
  32. N/A The Various Effects of Gaseous Albuterol on Serum Lactate Completed
  33. N/A Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics Completed
  34. N/A Characterization of Placebo Responses in Stable Asthma Completed
  35. N/A Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study Completed
  36. N/A Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults Completed
  37. N/A Respiratory Impedance and Obliterative Bronchiolitis Completed
  38. N/A Aerosolized Albuterol Use in Severe BPD Completed

Showing the 44 most-cited and recently-updated of 44 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.